Research Institute of Molecular Pathology
 |
|
| Established | 1985 |
|---|---|
| Research type |
|
|
Field of research
|
|
|
Director
|
Jan-Michael Peters (science); Harald Isemann (administration) |
| Faculty | 15 |
| Staff | 250 |
| Address | Campus-Vienna-Biocenter 1, 1030 Vienna, Austria |
| Location | Vienna, Austria |
| Website | www |
The Research Institute of Molecular Pathology (IMP) is a biomedical research center, which conducts curiosity-driven basic research in the molecular life sciences.
The IMP is located at the Vienna Biocenter in Vienna, Austria. The institute employs around 250 people from 36 nations, of which approximately 200 are scientists. The working language at the IMP is English. The IMP was established in 1985 and is funded by the pharmaceutical company Boehringer Ingelheim and research grants.
Research at the IMP aims to elucidate mechanisms and principles that underlie complex biological processes. Six general themes emerge from the work of the IMP research groups:
The research in these fields is pursued by 15 independent research groups, headed by principal investigators. The groups focus on the following topics:
The establishment of the IMP was a joint venture by Boehringer Ingelheim and Genentech and initiated in 1985. Under the directorship of Max Birnstiel, the first institute building was opened in 1988.
In 1992, three institutes of the faculties of science and medicine of the University of Vienna moved into a nearby building, today's Max F. Perutz Laboratories (MFPL). This created the basis for referring to the area as the "Vienna Biocenter" (VBC).
In 1993, Boehringer Ingelheim took over the IMP shares of Genentech. Following Max Birnstiel's retirement in 1997, Kim Nasmyth became scientific director.
In 2006, two institutes of the Austrian Academy of Sciences were opened in the vicinity of the IMP: the Institute of Molecular Biotechnology and the Gregor Mendel Institute (GMI). The three institutes cooperate closely by maintaining shared facilities. In the same year, Barry Dickson became the IMP's scientific director.
...
Wikipedia